BIOMAT Database Logo BIOMAT Database Logo

[5-FU concentration in the tissues (tumor and lymph node) of breast cancer patients given preoperative administration of UFT and FT]. 1985

T Koida, and M Kimura

In 16 patients with breast cancer who were administered UFT or FT-207 (UFT: 9 cases, FT-207: 7 cases) for a were prior to surgery, we studied the concentrations of 5-FU in the blood and tumor tissues, and in normal and metastatic lymph nodes sampled during surgery. As a result, a high level of 5-FU was found in tumors, especially in metastatic lymph nodes, in the patients who were administered UFT. On the other hand, no significant difference was found between the 5-FU levels of blood in UFT- and FT-treated patients. These facts suggest that UFT can be expected to increase antitumor activity without side effects, especially in cases of metastatic lymph nodes.

UI MeSH Term Description Entries
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D011300 Preoperative Care Care given during the period prior to undergoing surgery when psychological and physical preparations are made according to the special needs of the individual patient. This period spans the time between admission to the hospital to the time the surgery begins. (From Dictionary of Health Services Management, 2d ed) Care, Preoperative,Preoperative Procedure,Preoperative Procedures,Procedure, Preoperative,Procedures, Preoperative
D001940 Breast In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES. Breasts
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.

Related Publications

T Koida, and M Kimura
[5-FU concentration in tissues of gastric cancer patients with preoperative administration of UFT--especially in comparison with FT-207].
October 1985, Gan no rinsho. Japan journal of cancer clinics,
T Koida, and M Kimura
[The serum and tissue concentration of FT-207, 5'-DFUR and 5-FU in patients with breast cancer by preoperative administration of UFT and 5'-DFUR].
February 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
T Koida, and M Kimura
[Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT].
April 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
T Koida, and M Kimura
[5-FU, FT-207 and uracil concentrations in the serum and tissues of patients with cervical cancer after UFT oral administration].
February 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
T Koida, and M Kimura
[Study on the concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after administration of FT-207 suppositories].
August 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
T Koida, and M Kimura
[5-FU concentration in tumor tissue and the antitumor effect in patients with gastric cancer after oral administration of UFT].
September 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
T Koida, and M Kimura
[Studies on 5-FU concentration in serum and bladder tumor tissue after oral administration of UFT].
October 1986, Hinyokika kiyo. Acta urologica Japonica,
T Koida, and M Kimura
[FT-207 and 5-FU concentrations in brain tumor tissues, plasma and CSF after administration of FT-207 suppository].
April 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
T Koida, and M Kimura
[Relationship between tissue concentrations of 5-FU and degeneration of tissues after UFT administration in patients with bladder tumor].
October 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
T Koida, and M Kimura
[5-FU concentration in blood and tissue of patients with primary lung cancer after oral administration of UFT].
March 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!